NRX Pharmaceuticals (NRXP) said Tuesday its subsidiary Hope Therapeutics has entered into a definitive agreement to acquire the Kadima Neuropsychiatry Institute, an interventional psychiatry clinic based in California.
Financial terms of the transaction were not disclosed.
Kadima founder and medical director Dr. David Feifel will join Hope as its first chief medical innovation officer upon the closing of the acquisition, the company said.
Feifel has served as an elected member of the American College of Neuropharmacology and has held roles in multiple clinical trials for CNS therapies, according to the statement.
Shares of NRX Pharmaceuticals were up 2.6% in recent trading.
Price: 2.14, Change: +0.05, Percent Change: +2.64
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。